Sequence 2 from Patent US 20070264275

General Information


DRACP ID  DRACP01294

Peptide Name   Sequence 2 from Patent US 20070264275

Sequence  LGLPPDVQRV

Sequence Length  10

UniProt ID  P50757  P08253 

PubChem CID  Not available

Origin  Homo sapiens

Type  Native peptide

Classification

  

Active ACP



Activity Information


Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  Not available

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Antitumor



Structure Information


PDB ID  Not available

Predicted Structure  DRACP01294

Helicity  Not available

Linear/Cyclic  Not available

Disulfide/Other Bond  Not available

N-terminal Modification  Not available

C-terminal Modification  Not available

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C49H84N14O14

Absent amino acids  ACEFHIKMNSTWY

Common amino acids  LPV

Mass  125401

Pl  6.34

Basic residues  1

Acidic residues  1

Hydrophobic residues  4

Net charge  0

Boman Index  -1032

Hydrophobicity  9

Aliphatic Index  136

Half Life 
  Mammalian: 30 hour
  Yeast: >20 hour
  E.coli: >10 hour

Extinction Coefficient cystines  0

Absorbance 280nm  0

Polar residues  1

Amino acid distribution



Literature Information


Literature 1

Pubmed ID Not available

Title  Not available

Doi Not available

Year  Not available

Patent

Patent ID US 2007/0264275 A1

Patent Title  Peptides Derived from the Protein Mmp-3, and the Use Thereof in Antitumoral Immunotherapy.

Other Iinformation  Granted Patent Family: 8s / 8ex; Family Jurisdictions: US, CA, EP, JP, FR, WO; Legal Status: Inactive; Application No: 56195104; Filed:Jun 24, 2004; Published: Nov 15, 2007; Earliest Priority: Jun 25, 2003; Granted: Dec 8, 2009

Other Published ID  CA2529943A1  EP1635862A1  US7629439  WO2005000342A1 




DRACP is developed by Dr.Zheng's team.